Glucocorticoid-Induced Osteoporosis (GIO) Model
If you are looking for a robust and reliable provider of disease models to support your osteoporosis research, Creative Bioarray is the perfect partner for you. Our glucocorticoid-induced osteoporosis (GIO) model is designed to meet the highest standards of scientific rigor and can provide you with the data you need to advance your research goals.
Glucocorticoids, commonly employed for their anti-inflammatory and immunosuppressive properties, are associated with a significant iatrogenic complication: GIO. Prolonged exposure to high doses of glucocorticoids leads to osteoporosis in a considerable number of patients. It is well-established that excess glucocorticoids directly impact bone cells, including osteoblasts, osteoclasts, and osteocytes, disrupting their proliferation, differentiation, apoptosis, and other vital functions. These cellular alterations are believed to play a crucial role in the pathogenesis of GIO.
Fig. 1 Effects of GC excess on bone cell. GC, glucocorticoids
Our Glucocorticoid-Induced Osteoporosis (GIO) Model
- Available Animal
Rat - Modeling Method
Animals are treated with glucocorticoids (such as hydrocortisone or dexamethasone) to induce osteoporosis. - Endpoints
- Body weight
- Histology analysis: H&E staining
- Bone mineral density (BMD)
- Micro-CT
- Other customized endpoints
Example Data
Fig. 2 Effects of EGCG on trabecular bone micro-architecture in GIO rats. (A) micro-CT of proximal femurs. (B) Data from BMD measurements of femurs by DXA. The following computed tomographic indices were analyzed in the defined region of interest (ROI): (C) Tb.Th, (D) Tb.Sp, (E) Tb.N, (F) BV/TV, (G) Conn.D, and (H) SMI.
Furthermore, we also provide other osteoporosis models that maybe you are interested in:
Quotation and Ordering
Creative Bioarray is dedicated to sharing our extensive expertise in drug efficacy studies with our clients to facilitate and accelerate their drug development process. We specialize in developing and validating disease models that mimic human pathologies, providing a rigorous testing environment for your drug candidates. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly. We look forward to cooperating with you.
References
- Chen, M., et al. Pathogenic mechanisms of glucocorticoid-induced osteoporosis. Cytokine & growth factor reviews, 2023, 70: 54-66.
- Liu, S., et al. Epigallocatechin-3-gallate ameliorates glucocorticoid-induced osteoporosis of rats in vivo and in vitro. Frontiers in pharmacology, 2018, 9: 447.